SCHEMBL3015793

SCHEMBL3015793

O=S(=O)(c1cc(Cl)ccc1Cl)N1CCN(c2nc(Cc3cccc(Br)c3)cs2)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
TSHR P16473 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALOX15 P16050 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
USP2 O75604 1/20 0.40
PKM P14618 1/20 0.40
ALDH3A1 P30838 1/20 0.39
MAPT P10636 2/20 0.39
TRPV4 Q9HBA0 1/20 0.39
RECQL P46063 1/20 0.38
LMNA P02545 3/20 0.38
CNR1 P21554 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GBA1 P04062 1/20 0.38
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006210 0.93 TRPV4 (0.47) ALDH1A1TSHRMAPTTRPV4LMNA
SCHEMBL3013843 0.91 KMT2A (0.43) ALDH1A1MAPTTRPV4LMNAMEN1
SCHEMBL3654836 0.90 MAPT (0.48) ALDH1A1TSHRTDP1PKMMAPT
SCHEMBL3023185 0.89 TRPV4 (0.47) ALDH1A1TSHRTDP1ALOX15L3MBTL1
SCHEMBL3011745 0.89 RAB9A (0.36) ALDH1A1TSHRTDP1ALOX15L3MBTL1
SCHEMBL3011395 0.89 ALDH1A1 (0.49) ALDH1A1TSHRTDP1ALOX15L3MBTL1
SCHEMBL3015401 0.89 GBA1 (0.49) ALDH1A1TSHRL3MBTL1USP2MAPT
SCHEMBL3012841 0.89 TRPV4 (0.40) ALDH1A1L3MBTL1USP2PKMMAPT
SCHEMBL3007412 0.89 MEN1 (0.46) ALDH1A1TSHRL3MBTL1MAPTLMNA
SCHEMBL3022360 0.88 ALDH1A1 (0.47) ALDH1A1TSHRTDP1ALOX15L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885TSHR 3320/4885TDP1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.